Only Lyme Disease Vaccine In Development Goes To Phase 3 Trial

CNN.com - RSS Channel - Health, CNN: Health
Tue, 08/09/2022 - 2:10pm

Vaccine maker Pfizer says it has begun Phase 3 clinical trial of its vaccine candidate against Lyme disease with French vaccine company Valneva SE.

NEXT
Topics:  health   
RELATED ARTICLES
  • no title provided in feed
    The global fertility rate has fallen from 5 births per woman in 1950 to 2.3 in 2021 - and even lower in the U.S., partly due to the cost of child-rearing and shifts in priorities. But "falling population and an elderly or aging population puts a lot of fiscal and economic pressures on society," says Economics Professor Melissa Kearney. More
  • no title provided in feed
    Independent presidential candidate Robert F. Kennedy Jr. told The New York Times he experienced a series of health issues in recent years, including an abnormality that he said was caused by a worm that entered his brain and then died. More
  • no title provided in feed
    Americans' mental health issues are not identified and treated as readily as physical symptoms, especially among children - in part due to a shortage of clinicians. "We're looking for ways to integrate mental health into settings where children and families are every day," says Dr. More
  • no title provided in feed
    Mayor Donna Deegan speaks with CNN's Jake Tapper More
  • no title provided in feed
    Rep. Brad Wenstrup speaks with CNN's Jake Tapper More
  • no title provided in feed
    For some who see a therapist, just talking things through isn't enough. Drama therapy allows the patient to relive a moment or play out their biggest fears. More
BING NEWS:
  • First Volunteers Set to Get Experimental Lyme Disease Vaccine in Large Clinical Trial
    A large-scale trial for a crucially needed vaccine has just gotten underway. Over the weekend, the first volunteers enrolled in the trial testing out a Lyme disease vaccine candidate developed by ...
    06/18/2024 - 3:37 am | View Link
  • Merck Wins FDA Approval for First Pneumococcal Vaccine Designed for Adults
    Merck on Monday secured the FDA’s green light for its 21-valent pneumococcal vaccine Capvaxive, which covers serotypes responsible for around 84% of invasive pneumococcal disease cases.
    06/18/2024 - 1:41 am | View Link
  • Merck gets shot in the arm with FDA approval for first pneumococcal vaccine designed for adults
    The FDA has approved the world’s first pneumococcal disease vaccine designed for adults, signing off on Merck’s Capvaxive (formerly V116) and positioning it to become the primary shot used by seniors ...
    06/17/2024 - 10:03 am | View Link
  • New Merck pneumococcal vaccine wins FDA approval
    The vaccine is also designed to protect against infections that progress to the rarer but more life-threatening invasive pneumococcal disease, which can take the form of bloodstre ...
    06/17/2024 - 9:55 am | View Link
  • Moderna’s Next-Gen COVID Vaccine Beats Current Shot in Pivotal Adult Efficacy Trial
    Moderna said Thursday it plans to talk to regulators about the next steps after showing its next-generation candidate is more efficacious in adults than the biotech’s existing Spikevax COVID-19 shot.
    06/13/2024 - 4:49 am | View Link
  • More

 

NEXT